Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Literature
1.
Terbah R, Chapman B, Gow P, Sinclair M, Angus P, Testro A. The efficacy, safety, and tolerability of outpatient continuous terlipressin infusion in patients awaiting liver transplantation. J Gastroenterol Hepatol. 2019;34:105.
2.
Vasudevan A, Ardalan Z, Gow P, Angus P, Testro A. Efficacy of outpatient continuous terlipressin infusions for hepatorenal syndrome. Hepatology. 2016;64:316–318.CrossRef
3.
Chapman B, Gow P, Angus P, Sinclair M, Testro A. Outpatient terlipressin infusion increases dietary intake and functional muscle strength in patients awaiting liver transplant. J Hepatol. 2018;68:S726.CrossRef
4.
Angeli P, Ginès P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut. 2015;64:531–537.CrossRef
5.
Cavallin M, Piano S, Romano A, et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study. Hepatology. 2016;63:983–992.CrossRef
6.
7.
Boyer TD, Sanyal AJ, Wong F, et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology. 2016;150:1579–1589.e1572.CrossRef
8.
European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69:406–460.CrossRef
9.
Late-Breaking Abstracts—Presented at the 70th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting™ 2019. Hepatology. 2019;70:1477a–1501a.
10.
Angeli P, Ginès P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015;62:968–974.CrossRef
Metadata
Title
Terlipressin for Type 1 Hepatorenal Syndrome
Authors
R. Terbah
P. Gow
M. Sinclair
A. Testro
Publication date
01-08-2020
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 8/2020
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-020-06370-8

Other articles of this Issue 8/2020

Digestive Diseases and Sciences 8/2020 Go to the issue

UNM CLINICAL CASE CONFERENCES

Liver Abscess: A Wolf in Sheep’s Clothing

Correspondence

Repurposed GI Drugs in the Treatment of COVID-19

Original Article

Breath Test Gas Patterns in Inflammatory Bowel Disease with Concomitant Irritable Bowel Syndrome-Like Symptoms: A Controlled Large-Scale Database Linkage Analysis

FELLOWS AND YOUNG GIS SECTION

Outrunning Burnout in a GI Fellowship Program During the COVID-19 Pandemic

DDS AUTHOR PROFILES

Author Spotlight: Mohammad Bilal

Original Article

Corticosteroid Treatment at Diagnosis: An Analysis of Relapses, Disease Extension, and Colectomy Rate in Ulcerative Colitis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits